[HTML][HTML] PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol, and atherosclerosis in the absence of ApoE [S]

B Ason, JWA van der Hoorn, J Chan, E Lee… - Journal of lipid …, 2014 - ASBMB
LDL cholesterol (LDL-C) contributes to coronary heart disease. Proprotein convertase
subtilisin/kexin type 9 (PCSK9) increases LDL-C by inhibiting LDL-C clearance. The
therapeutic potential for PCSK9 inhibitors is highlighted by the fact that PCSK9 loss-of-
function carriers exhibit 15–30% lower circulating LDL-C and a disproportionately lower risk
(47–88%) of experiencing a cardiovascular event. Here, we utilized pcsk9−/− mice and an
anti-PCSK9 antibody to study the role of the LDL receptor (LDLR) and ApoE in PCSK9 …